MD Anderson and Rigel partner to expand olutasidenib evaluat

The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia (AML) and other hematologic cancers.

Related Keywords

Texas , United States , Raul Rodriguez , Courtney Dinardo , Drug Administration , Rigel Pharmaceuticals Inc , University Of Texas Md Anderson Cancer Center , Manderson Cancer , Cancer Center , Rigel Pharmaceuticals , Pharmaceuticals , Acute Myeloid Leukemia , Dancer , Leukemia , Olecule , Myelodysplastic Syndromes , Myeloid Leukemia , Research ,